Connect with us

Business

GSK Agrees to Acquire Nuvalent for $10.6 Billion in Major Oncology Deal, Sending Shares Soaring 39%

Published

on

Moderna MRNA Stock 2026 Outlook: Buy or Sell the mRNA

NEW YORK — Nuvalent Inc. shares skyrocketed more than 38% in early trading Tuesday after British pharmaceutical giant GSK announced a $10.6 billion all-cash agreement to acquire the Boston-based clinical-stage biotechnology company focused on precision oncology therapies for lung cancer.

Nuvalent stock jumped to around $122.87, up $34.38 or 38.85% from Monday’s close, trading near the $124 per share offer price as investors reacted to the significant premium. The deal values the company at an equity total of approximately $10.6 billion, or $9.4 billion net of cash, representing a 40% premium to the prior closing price and a 26% premium to the 30-day volume-weighted average price.

Under the terms, GSK will commence a tender offer to acquire all outstanding shares of Nuvalent’s Class A and Class B common stock at $124 per share in cash. The transaction is expected to close in the second half of 2026, subject to customary conditions including regulatory approvals and the tender of a majority of shares.

The acquisition bolsters GSK’s oncology portfolio with Nuvalent’s promising pipeline of targeted therapies for ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). Nuvalent’s lead candidates, zidesamtinib and neladalkib, have shown strong clinical activity in heavily pretreated patients, including those with brain metastases and resistance mutations, addressing key limitations of existing treatments.

Advertisement

GSK highlighted the strategic fit, noting Nuvalent’s focus on validated targets with potential to overcome efficacy and tolerability issues in current standards of care. The deal includes multiple assets in lung cancer, a high-priority area for the British drugmaker as it seeks to strengthen its innovative medicines pipeline.

Nuvalent, founded in 2017, specializes in developing small-molecule inhibitors designed for precision targeting of kinase-driven cancers. Its candidates aim to provide better brain penetration and selectivity compared to earlier-generation therapies, potentially improving outcomes for patients with advanced disease. Positive pivotal data from trials like ALKOVE-1 and ARROS-1 had already positioned the company as an attractive player in the competitive oncology space.

The announcement marks one of the largest biotechnology acquisitions of 2026, underscoring continued big pharma interest in late-stage oncology assets amid patent cliffs and the need for innovative pipelines. For Nuvalent shareholders, the premium represents substantial value realization after years of clinical development.

Company executives expressed enthusiasm about the combination. The deal allows Nuvalent’s science to advance under GSK’s global resources while delivering immediate and attractive returns to investors. GSK reiterated its commitment to its dividend policy and 2026 guidance despite the investment.

Advertisement

Wall Street analysts had been bullish on Nuvalent prior to the news, with consensus price targets well above previous trading levels citing its differentiated pipeline and potential for multiple approvals. The GSK offer exceeds many of those targets, validating the company’s progress in precision oncology.

The surge in trading volume reflected widespread investor excitement, with shares hitting new record highs intraday. Market watchers noted the deal’s structure as a clean all-cash tender, reducing uncertainty and providing a clear path to completion. Regulatory reviews are anticipated to focus on antitrust considerations in the oncology sector, though the targeted nature of the assets may limit concerns.

For the broader biotechnology sector, such transactions highlight the value of innovative clinical assets in a challenging funding environment. Nuvalent’s success in advancing candidates to late-stage development and regulatory submissions has made it an appealing target for larger players seeking near-term revenue drivers.

GSK’s move aligns with industry trends of consolidation in oncology, where large companies leverage acquisitions to complement internal research and accelerate growth. The British firm has been active in dealmaking to rebuild its pipeline following several patent expirations.

Advertisement

Nuvalent’s pipeline includes zidesamtinib for ROS1-positive NSCLC and neladalkib for ALK-positive disease, both with encouraging data in pretreated populations and potential in frontline settings. Positive results presented at major medical meetings had de-risked the programs and attracted significant attention.

The acquisition is expected to have minimal immediate impact on GSK’s 2026 financial guidance. The company emphasized that the transaction supports its long-term strategy without compromising shareholder returns through dividends.

Biotechnology investors often view such deals as validation of platform technologies and clinical execution. For Nuvalent, which went public in 2021, the agreement caps a rapid ascent from early research to a multibillion-dollar exit. The premium rewards patience from long-term holders and early backers.

As the tender offer process begins, shareholders will evaluate the offer against any potential superior proposals, though the substantial premium and strategic fit make competing bids less likely. The deal is structured to close efficiently once conditions are satisfied.

Advertisement

The news provides a positive backdrop for the broader biotech sector, where M&A activity has been a key driver amid volatile public markets. Companies with strong clinical data in high-unmet-need areas continue to attract interest from strategic buyers.

Nuvalent will continue operations as usual pending closing, with ongoing clinical trials and regulatory activities advancing. The combination is expected to accelerate development and commercialization of its therapies on a global scale under GSK’s infrastructure.

Market reaction extended beyond Nuvalent, with modest gains in other precision oncology names as investors assessed potential ripple effects. The deal reinforces confidence in the long-term value of targeted cancer therapies despite periodic sector volatility.

As details emerge in the coming days, attention will turn to integration plans, regulatory timelines and potential synergies. For now, the announcement delivers significant value to Nuvalent shareholders while positioning GSK to strengthen its presence in lung cancer treatments.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Bitcoin Steadies Near $64,000 as Crypto Traders Brace for a Pivotal Federal Reserve Rate Decision Today

Published

on

Robinhood logo.

Bitcoin traded at $63,860.26 as of Wednesday afternoon, up a modest $13.14, or roughly 0.02%, as cryptocurrency markets settled into a holding pattern ahead of a Federal Reserve interest rate decision that traders across both traditional and digital asset markets have described as unusually difficult to predict.

Bitcoin opened Wednesday at $63,853.49, up 0.2% from Tuesday’s opening price, before climbing as high as $64,244.18 during the morning session, according to pricing data. The cryptocurrency’s relatively flat overall movement Wednesday followed a volatile stretch earlier in the week, including a sharp pullback Tuesday when bitcoin opened 2.5% lower than the previous day, dropping to around $63,327 as investors broadly reduced exposure to riskier assets ahead of the Fed’s two-day policy meeting.

The Federal Reserve’s rate decision, due later Wednesday, has emerged as the dominant catalyst shaping crypto market sentiment this week. According to data from the CME Group’s FedWatch tool, market participants assigned a 35.8% probability to a rate increase following the meeting’s conclusion, up sharply from 25.7% just a week earlier. Separate estimates cited by CoinDesk showed a somewhat different split, with roughly a 70% probability assigned to rates remaining unchanged and a 30% chance of a surprise quarter-point increase. Some analysts have characterized the meeting as among the hardest Fed decisions to forecast in recent years, given the unusual combination of economic signals policymakers are currently weighing.

Ether, the second-largest cryptocurrency by market value, moved somewhat more sharply than bitcoin during the same period. Ethereum opened Wednesday at $1,919.73, up 1.5% from Tuesday’s opening price, before slipping back to $1,904.82 by mid-morning, according to pricing data. Bitcoin and ether moved in opposite directions for stretches of Wednesday’s session, a divergence that market watchers attributed to renewed airstrikes in the Middle East combined with the approaching Fed announcement, both of which have added competing sources of uncertainty for crypto investors this week.

Advertisement

Broader cryptocurrency market data showed modest overall improvement heading into Wednesday. The total global cryptocurrency market capitalization rose 0.4% to reach approximately $2.28 trillion, recovering from a 1.6% decline recorded the previous day, according to data from CoinMarketCap. Bitcoin’s dominance within the broader crypto market held steady at approximately 56.3%, while ether accounted for roughly 10.2% of total market value. Despite the modest recovery in headline prices, a widely tracked measure of investor sentiment, the Fear and Greed Index, remained in “fear” territory at a reading of 28 to 29, reflecting continued caution among traders even as prices stabilized somewhat.

Institutional flows into bitcoin exchange-traded funds showed signs of softening in recent sessions. Spot bitcoin ETFs recorded a net outflow of $11.6 million on July 27, ending a streak of seven consecutive sessions of net inflows, with asset managers BlackRock and Fidelity leading the pullback, according to data on ETF flows. Even so, some corporate treasury activity continued during the same window, with Hyperscale Data disclosing a bitcoin treasury holding of 1,106 bitcoin, valued at approximately $71.7 million, as of July 28, signaling that at least some institutional accumulation of the cryptocurrency has continued despite broader market softness.

Macroeconomic factors beyond the Fed decision have also weighed on crypto sentiment this week. Rising oil prices, driven by renewed hostilities between the United States and Iran, have added to broader inflation concerns across financial markets, a dynamic that traditionally creates headwinds for risk assets including cryptocurrencies. At the same time, a strengthening U.S. dollar has added further pressure, with analysts noting that the combination of higher oil prices and dollar strength has increased overall macro-volatility risk heading into the Fed’s announcement.

Trading data suggested bitcoin has largely oscillated within a defined range in recent sessions, generally trading between roughly $62,700 and $65,500. Some market analysts have pointed to that range as a key technical zone to watch in the near term, with the lower boundary near $62,700 serving as a support level and the $64,500 to $65,500 zone acting as resistance that bitcoin has struggled to convincingly break through in recent trading.

Advertisement

Beyond bitcoin and ether, individual cryptocurrency tokens showed more significant divergence Wednesday. Jupiter, a decentralized finance token, rose nearly 6% to lead gains within a broader recovery among DeFi-focused tokens, while artificial intelligence-linked tokens continued to struggle, with Fetch.ai falling more than 4% on the day as AI-related crypto tokens continued unwinding gains posted the previous month.

Bitcoin’s current price level remains well below its all-time highs reached earlier in the cryptocurrency’s price cycle, though the asset has still posted substantial gains compared with prior years, with its market capitalization standing at approximately $1.27 trillion to $1.33 trillion depending on the specific pricing snapshot used, maintaining its position as by far the largest cryptocurrency by market value, well ahead of ether’s market capitalization of roughly $233 billion.

With the Federal Reserve’s decision expected to be announced later Wednesday, crypto traders and analysts broadly expect increased volatility to follow the announcement, regardless of whether the central bank opts to raise rates, hold steady, or signal a different policy path than markets currently anticipate, given how closely digital asset prices have tracked broader shifts in monetary policy expectations throughout the past several weeks of trading.

Advertisement
Continue Reading

Business

Amazon Web Services India net profit jumps over 10-fold to Rs 242 cr in FY26

Published

on

Amazon Web Services India net profit jumps over 10-fold to Rs 242 cr in FY26
Amazon Web Services India Pvt Ltd has reported a more than 10-fold growth in consolidated net profit to Rs 242.8 crore in the financial year 2026, as per a document shared by market intelligence firm Tofler.

The cloud services arm of e-commerce giant Amazon had posted net profit of Rs 23.1 crore in FY25.

​Its consolidated revenue from operations grew by about 21 per cent to Rs 20,225.6 crore in FY26 from Rs 16,744.9 crore in FY25.

AWS, however, reported a decline of around 14 per cent in standalone net profit to Rs 242.4 crore in FY26, compared to Rs 281.5 crore in FY25.

Advertisement

The company’s revenue from operations on a standalone basis grew by 21.4 per cent to Rs 20,225.6 crore during the period under review from Rs 16,659 crore in the year-ago period.


“The company’s total expenses for the fiscal were reported at Rs 19,888 crore (on a standalone basis),” Tofler said.

Continue Reading

Business

Heathrow passengers to foot bill for third runway bidding process

Published

on

Business Live

The initial costs are expected to be recouped through ticket prices

a British Airways plane taking off from Heathrow Airport

A British Airways plane taking off from Heathrow Airport(Image: Daniel Leal-Olivas/PA Wire)

Heathrow will be allowed to pass the enormous bill it has accumulated in preparing its third runway bid on to passengers, the aviation watchdog has confirmed, in a ruling that looks set to cement the airport’s status as the costliest in the world.

The Civil Aviation Authority (CAA) ruled that Heathrow Airport Limited (HAL) will be entitled to recoup the £320m it has already spent competing to secure the megaproject contract by increasing the fees attached to travellers’ air fares.

Advertisement

Rival bidder Heathrow West was also granted permission to recover the £4.2m it has so far spent on its own proposal.

The two operators have been competing fiercely to persuade ministers to back their respective third runway plans, assembling extensive planning documents and feasibility studies, while also enlisting the services of expensive third-party advisers to bolster their bids.

For incumbent HAL, that investment has already stretched into the hundreds of millions, the CAA noted, with the hub previously arguing it needs to cover its early outlay if the expansion is to remain financially attractive, reports City AM.

In its ruling, the aviation regulator said without the design and planning efforts both bidders have undertaken to develop credible expansion proposals, the timely delivery of the third runway project would have been put at risk.

Advertisement

It added that both parties would need to demonstrate their claims had been independently scrutinised line by line before being permitted to pass on the costs.

“Our decision strikes a balance between supporting the delivery of benefits to consumers through timely progress on Heathrow expansion, whilst also protecting them from undue increases in costs,” said Tim Johnson, the UK Civil Aviation Authority’s director of consumers and markets.

“The costs Heathrow can recover are capped, independently scrutinised and subject to efficiency reviews, helping ensure that passengers only pay for efficient costs that are justified.”

Under the compensation scheme, agreed following a consultation held last year, HAL will be permitted to add 10p to every passenger fare over the next 20 to 25 years. It will also be responsible for recouping Heathrow West’s more modest costs, should the rival bid led by hotel magnate Surinder Arora fail to succeed.

Advertisement

The CAA reached its decision alongside a wide-ranging review of Heathrow’s overarching regulatory framework, in which it will determine whether rival operators will be permitted to own and run key infrastructure within the airport.

Airlines operating at the hub have grown increasingly frustrated with the exorbitant charges they are forced to pass on to passengers, and – in lockstep with Arora – some have established a pressure group lobbying for a wholesale shake-up of red tape at the airport.

At £28.80, the airport’s charges are already the costliest in the world, and are anticipated to climb by as much as £50 once the full expenditure of the third runway is factored in.

Wednesday’s CAA ruling will see the airport charge per passenger rise by approximately 15 pence in 2028, climbing to 30 pence in subsequent years.

Advertisement

The initial costs incurred by bidders are expected to be recouped through ticket prices over a period of roughly 20 to 25 years.

Continue Reading

Business

Automatic Data Processing, Inc. (ADP) Q4 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript